OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Commerce. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
December 11, 2023
Phase III INTerpath-002 trial will evaluate the novel individualized neoantigen therapy V940 (mRNA-4157) with Keytruda (pembrolizumab) as an adjuvant treatment for patients with non-small cell lung cancer.
Adults and children aged 1 year and older are eligible for the IV formulation of
Cresemba for invasive aspergillosis and invasive mucormycotic, whereas the prescribed capsule is only indicated for adults and children 6 years of age and older.
December 08, 2023
The rise in demand represents the third consecutive month of year-on-year growth.
FDA approves bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, which affects approximately 100,000 people in the United States.
December 07, 2023
An independent Data Monitoring Committee found that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit vs. Keytruda in combination with chemotherapy followed by Keytruda plus a placebo in patients with metastatic squamous non-small cell lung cancer.
December 06, 2023
Novartis anticipates Fabhalta to be available in the United States in December for the treatment of paroxysmal nocturnal hemoglobinuria.